- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/92 - Naphthostyrils
Patent holdings for IPC class C07D 209/92
Total number of patents in this class: 23
10-year publication summary
|
1
|
1
|
2
|
2
|
1
|
5
|
3
|
1
|
4
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| C4 Therapeutics, Inc. | 97 |
8 |
| Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences | 132 |
3 |
| Mississippi State University | 172 |
2 |
| Revvity Health Sciences, Inc. | 305 |
2 |
| Guangzhou National Laboratory | 66 |
2 |
| PerkinElmer Health Sciences, Inc. | 198 |
1 |
| Samjin Pharmaceutical Co., Ltd. | 48 |
1 |
| University of Tennessee Research Foundation | 763 |
1 |
| Hangzhou Glubio Pharmaceutical Co., Ltd. | 14 |
1 |
| Shanghai Helioson Pharmaceutical Co., Ltd. | 8 |
1 |
| Lancetome (Beijing) Biotech Ltd. | 1 |
1 |
| Other owners | 0 |